Literature DB >> 10877041

Fluoroquinolone-induced renal failure.

B M Lomaestro1.   

Abstract

Fluoroquinolones are generally well tolerated, clinically useful antimicrobials. This paper highlights rare, but potentially serious, adverse effects involving the kidney. Other antimicrobials have long been known to cause various forms of nephrotoxicity occurring as allergic interstitial nephritis, granulomatous interstitial nephritis, necrotising vasculitis, allergic tubular nephritis or a tubular necrosis. A Medline search (1985 to May 1999) of ciprofloxacin, norfloxacin, levofloxacin, ofloxacin, trovafloxacin, enoxacin, sparfloxacin, grepafloxacin, gatifloxacin, clinafloxacin and moxifloxacin was conducted to ascertain the incidence and features of fluoroquinolone nephrotoxicity. Unfortunately, the data primarily consist of case reports and temporally related events. The incidence of these adverse effects is hard to estimate, and the cause may be multifactorial. While the use of ciprofloxacin appears to increase the risk, this may be due to its longer and more widespread use when compared with the newer agents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10877041     DOI: 10.2165/00002018-200022060-00006

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  32 in total

1.  Renal vasculitis associated with ciprofloxacin.

Authors:  D J Shih; S M Korbet; J J Rydel; M M Schwartz
Journal:  Am J Kidney Dis       Date:  1995-09       Impact factor: 8.860

2.  Ciprofloxacin-induced acute interstitial nephritis.

Authors:  R J Reece; A J Nicholls
Journal:  Nephrol Dial Transplant       Date:  1996-02       Impact factor: 5.992

3.  Case report of renal failure during norfloxacin therapy.

Authors:  J Boelaert; P P de Jaegere; R Daneels; M Schurgers; B Gordts; H W van Landuyt
Journal:  Clin Nephrol       Date:  1986-05       Impact factor: 0.975

Review 4.  Acute renal failure due to ciprofloxacin.

Authors:  M Allon; E J Lopez; K W Min
Journal:  Arch Intern Med       Date:  1990-10

5.  Acute interstitial nephritis in a cardiac transplant recipient receiving ciprofloxacin.

Authors:  L J Rosado; M S Siskind; J G Copeland
Journal:  J Thorac Cardiovasc Surg       Date:  1994-05       Impact factor: 5.209

6.  Renal failure and quinolone.

Authors:  M Godin; T Ducastelle; E Bercoff; D Dubois; J P Fillastre; J Bourreille
Journal:  Nephron       Date:  1984       Impact factor: 2.847

7.  Crystalluria and ciprofloxacin, influence of urinary pH and hydration.

Authors:  S B Thorsteinsson; T Bergan; S Oddsdottir; R Rohwedder; R Holm
Journal:  Chemotherapy       Date:  1986       Impact factor: 2.544

Review 8.  Ciprofloxacin overdose: acute renal failure with prominent apoptotic changes.

Authors:  V R Dharnidharka; K Nadeau; C L Cannon; H W Harris; S Rosen
Journal:  Am J Kidney Dis       Date:  1998-04       Impact factor: 8.860

Review 9.  Antibiotic-related nephrotoxicity.

Authors:  G J Kaloyanides
Journal:  Nephrol Dial Transplant       Date:  1994       Impact factor: 5.992

10.  Ciprofloxacin-induced renal dysfunction in patients with mycobacterial lung infections.

Authors:  W W Yew; C H Chau; P C Wong; H Y Choi
Journal:  Tuber Lung Dis       Date:  1995-04
View more
  12 in total

1.  Lack of effect of DX-619, a novel des-fluoro(6)-quinolone, on glomerular filtration rate measured by serum clearance of cold iohexol.

Authors:  Nenad Sarapa; Prachi Wickremasingha; Nanxiang Ge; Richard Weitzman; Merynda Fuellhart; Cindy Yen; Julia Lloyd-Parks
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

2.  Sustained ocular delivery of ciprofloxacin using nanospheres and conventional contact lens materials.

Authors:  Rahul Garhwal; Sally F Shady; Edward J Ellis; Jeanne Y Ellis; Charles D Leahy; Stephen P McCarthy; Kathryn S Crawford; Peter Gaines
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-03-13       Impact factor: 4.799

3.  Fluoroquinolone-induced serious, persistent, multisymptom adverse effects.

Authors:  Beatrice Alexandra Golomb; Hayley Jean Koslik; Alan J Redd
Journal:  BMJ Case Rep       Date:  2015-10-05

Review 4.  Safety considerations of fluoroquinolones in the elderly: an update.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

Review 5.  Current therapy of inflammatory bowel disease in children.

Authors:  Paul A Rufo; Athos Bousvaros
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

6.  A case of acute renal failure in a patient recently treated with clozapine and a review of previously reported cases.

Authors:  J Daniel Kanofsky; Mary E Woesner; Alexander Z Harris; James P Kelleher; Karen Gittens; Elina Jerschow
Journal:  Prim Care Companion CNS Disord       Date:  2011

Review 7.  Fluoroquinolones in the elderly: safety considerations.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions.

Authors:  Roberto Leone; Mauro Venegoni; Domenico Motola; Ugo Moretti; Valentina Piazzetta; Alfredo Cocci; Domenico Resi; Federico Mozzo; Giampaolo Velo; Liliana Burzilleri; Nicola Montanaro; Anita Conforti
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  Identification of enoxacin as an inhibitor of osteoclast formation and bone resorption by structure-based virtual screening.

Authors:  David A Ostrov; Andrew T Magis; Thomas J Wronski; Edward K L Chan; Edgardo J Toro; Richard E Donatelli; Kristen Sajek; Ireni N Haroun; Michael I Nagib; Ana Piedrahita; Ashley Harris; L Shannon Holliday
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

10.  Risk of acute kidney injury associated with the use of fluoroquinolones.

Authors:  Steven T Bird; Mahyar Etminan; James M Brophy; Abraham G Hartzema; Joseph A C Delaney
Journal:  CMAJ       Date:  2013-06-03       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.